Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CHMP recommends approval of Bristol Myers Squibb’s Reblozyl
The European Commission (EC) will now review the recommendation. On receiving approval, this would represent the third authorised indication for the therapy in the EU. Approved in the
The European Commission (EC) will now review the recommendation. On receiving approval, this would represent the third authorised indication for the therapy in the EU. Approved in the
Lecanemab is an investigational anti-amyloid beta (Aβ) protofibril antibody intended to treat AD with confirmed amyloid pathology. On 6 January, it received accelerated approval from the US Food
The funding round has seen participation of current investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven. As part of the investment,
Under the terms of the partnership deal between the companies, Hyloris will receive a share on any revenues related to product, such as royalties, license fees, milestone payments,
Serving as the primary IND for TScan’s solid tumour programme, T-Plex will enable customised combinations of T cell receptor (TCR)-engineered T cell therapies (TCR-T) to be given to
MFDS concluded that GX-188E met the criteria for this designation after assessing the complete set of Phase II results from the clinical trial that was recently completed in
In December last year, Evaxion secured the FDA approval to advance with its Phase IIb clinical trial, where EVX-01 is given along with KEYTRUDA to patients with metastatic
The recombinant adeno-associated virus (rAAV)-based gene therapy is being studied to treat neovascular Age Related Macular Degeneration (nAMD), which causes severe loss of vision and irreversible blindness across
The adeno-associated viral serotype rh10 (AAVrh10) gene therapy FBX-101 is delivered intravenously after hematopoetic stem cell transplant (HSCT) infusion. The designation for this lead adeno-associated virus (AAV) drug
The tocilizumab injection, BAT1806 is a recombinant humanised monoclonal antibody which has been developed to target interleukin-6 receptor (IL-6R). IL-6R specially binds to soluble and membrane-bound IL-6 receptors